GTx GTXI 深 沪
等待开盘 02-05 09:30:00 美东时间
1.20
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 1.20
- 总市值 2199.00万
- 52周最高 358.40
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 24.00
- 委 比 0.00%
- 总股本 1832.50万
- 历史最高 10136.00
- 量 比 0
- 振 幅 0.00%
- 历史最低 24.00
- 每 手 1
- 风险率 0.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Raymond James Initiates Coverage On MeiraGTx Hldgs with Strong Buy Rating, Announces Price Target of $29
Raymond James analyst Christopher Raymond initiates coverage on MeiraGTx Hldgs (NASDAQ:MGTX) with a Strong Buy rating and announces Price Target of $29.
2025-10-22 01:40
Grace Therapeutics Awarded Patent Titled "Nimodipine Parenteral Administration" From U.S. Patent and Trademark Office. Patent Covers Dosing Regimen For Intravenous Nimodipine Used In Phase 3 Strive-On Safety Trial For GTX-104
Grace Therapeutics, Inc. (NASDAQ:GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for I.V.
2025-09-18 20:38
FDA Accepts Grace Therapeutics’ NDA for GTx-104
Grace Therapeutics ( ($GRCE) ) has issued an update. On August 22, 2025, the FD...
2025-08-27 20:29
FDA Accepts Grace Therapeutics' New Drug Administration For GTx-104 For Formal Review
FDA Establishes April 23, 2026 as PDUFA Target Date for Review of Submission Seeking Approval for GTx-104 in the Treatment of Patients with aneurysmal Subarachnoid Hemorrhage (aSAH)Comprehensive Data Package Supported by
2025-08-27 20:03
Chardan Capital Maintains Buy on MeiraGTx Hldgs, Maintains $35 Price Target
Chardan Capital analyst Daniil Gataulin maintains MeiraGTx Hldgs (NASDAQ:MGTX) with a Buy and maintains $35 price target.
2025-08-15 19:29
MeiraGTx Hldgs Q2 EPS $(0.48) Misses $(0.46) Estimate, Sales $3.691M Miss $8.003M Estimate
MeiraGTx Hldgs (NASDAQ:MGTX) reported quarterly losses of $(0.48) per share which missed the analyst consensus estimate of $(0.46) by 5.03 percent. This is a 36.84 percent increase over losses of $(0.76) per share from
2025-08-14 20:06
Grace Therapeutics Submits NDA To FDA For GTx-104; Submission Seeks Approval Of GTx-104 In Treatment Of Patients With Aneurysmal Subarachnoid Hemorrhage
Submission Seeks Approval of GTx-104 in the Treatment of Patients with aneurysmal Subarachnoid Hemorrhage (aSAH)Comprehensive Data Package Includes Positive Results from Phase 3 STRIVE-ON Safety Trial of
2025-06-25 20:02
NTNX, WSM and GCO among midday movers
Gainers: Stellar Biotechnologies (NASDAQ: SBOT ) . Genocea Biosciences (...
2019-06-01 00:55
Gtx Inc盘中异动 大幅上涨5.71%
北京时间2019年05月31日22时35分，Gtx Inc（GTXI.us）股票出现异动，股价急速上涨5.71%。截至发稿，该股报1.11美元/股，成交量10...
2019-05-31 22:35
Gtx Inc盘中异动 大幅上涨7.00%报1.07美元
北京时间2019年05月28日21时44分，Gtx Inc（GTXI.us）股票出现波动，股价急速上涨7.00%。截至发稿，该股报1.07美元/股，成交量2....
2019-05-28 21:44
